We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

688521:SSEVeriSilicon Microelectronics (Shanghai) Co., Ltd. Class A Analysis

Data as of 2026-03-16 - not real-time

CN¥208.01

Latest Price

8/10Risk

Risk Level: High

Executive Summary

VeriSilicon trades above its 20‑day moving average but remains well below the 200‑day average, indicating a short‑term bullish bias within a longer‑term downtrend. The RSI sits in the low‑40s, suggesting neither overbought nor oversold conditions, while the MACD histogram is firmly negative, flagging bearish momentum. Revenue growth is robust at over 30% year‑over‑year, yet the company posts negative operating and profit margins, zero operating cash flow, and a high forward price‑to‑earnings multiple that dwarfs the industry average, pointing to severe valuation compression. Liquidity appears stable with consistent trading volume, but the stock exhibits extreme 30‑day volatility exceeding 100% and a modest beta, implying price swings are driven by company‑specific factors rather than market moves. The balance sheet shows a sizable debt load relative to equity, and the lack of dividend or free cash flow further limits defensive appeal. Overall, the technical setup shows a fragile bullish tilt, but fundamental weaknesses and an inflated valuation dominate the outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Price above short‑term SMA but below long‑term SMA
  • Negative MACD histogram indicating bearish momentum
  • High near‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth but persistent losses
  • Forward PE vastly above industry norm
  • Stable trading volume supporting liquidity

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Overvalued price relative to earnings prospects
  • Negative operating cash flow and high debt ratio
  • Lack of dividend and free cash flow sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth33.60%
Profit Margin-16.74%
P/E Ratio1131.9
ROE-18.61%
Debt/Equity39.94
P/B Ratio30.8
Industry P/E33.7

Technical Analysis

TrendBullish
RSI43.7
SupportCN¥200.00
ResistanceCN¥288.00
MA 20CN¥241.04
MA 50CN¥205.54
MA 200CN¥148.46
MACDBearish
VolumeStable
Fear & Greed Index76.7

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta0.24
Volatility103.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.